Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13048725 | 0.91 | CYP4F2 (0.43) | CYP4F2CYP4A11NPSR1 | |
| SCHEMBL6730542 | 0.83 | CYP3A4 (0.35) | CYP4F2CYP4A11NPSR1CYP3A4CYP2C19 | |
| SCHEMBL8278858 | 0.81 | CYP4F2 (0.50) | CYP4F2CYP4A11NPSR1MEN1CYP3A4 | |
| SCHEMBL7435656 | 0.79 | CYP2C19 (0.50) | CYP2C19ALDH1A1CETP | |
| SCHEMBL15572899 | 0.79 | CYP4F2 (0.51) | CYP4F2CYP4A11NPSR1MEN1CYP3A4 | |
| SCHEMBL7364717 | 0.79 | CYP4F2 (0.38) | CYP4F2CYP4A11 | |
| SCHEMBL6358085 | 0.79 | CYP2D6 (0.42) | MEN1CYP3A4KMT2ACYP2C19ALDH1A1 | |
| SCHEMBL6875644 | 0.77 | CYP4F2 (0.46) | CYP4F2CYP4A11NPSR1MEN1CYP3A4 | |
| SCHEMBL6735060 | 0.77 | SMN1; SMN2 (0.38) | MEN1KMT2AALDH1A1 | |
| SCHEMBL7365053 | 0.77 | CYP2C19 (0.47) | CYP4F2CYP4A11CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816326-B2 | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816326-B2 | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816326-B2 | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2134739-A2 | SULFUR COMPOUNDS AS INHIIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008124148-A2 | SULFUR COMPOUNDS AS INHIIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20070197448-A1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197448-A1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197448-A1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20040266764-A1 | Hydroxamic acid derivatives | HANNAH DUNCAN ROBERT | 2004-12-30 | — | — | US | disclosed |
| US-6809100-B2 | 2-(4-(4-FURAN-2-YLPHENYL)PIPERAZINE-1-SULFONYLMETHYL)-N-HYDROXY -3-METHYLBUTYRAMIDE, FOR EXAMPLE; TREATMENT OF CANCER, INFLAMMATION, OR AN AUTOIMMUNE, INFECTIOUS OR OCULAR DISEASE | DARWIN DISCOVERY LTD. (GB) | 2004-10-26 | — | — | US | disclosed |
| US-6787536-B2 | A HYDROXAMIC ACID COMPOUND CONTAINING HETEROAROMATIC RING ATTACHED TO SULFONYL GROUP THROUGH NITROGEN ATOM, INHIBITOR OF MATRIX METALLOPRETEINASE, USEFUL FOR TREATING DEGENERATIVE DISEASES AND CERTAIN CANCER | DARWIN DISCOVERY LIMITED (GB) | 2004-09-07 | — | — | US | disclosed |
| US-20030216404-A1 | Hydroxamic acid derivatives | HANNAH DUNCAN ROBERT (GB) | 2003-11-20 | — | — | US | disclosed |
| EP-1282614-B1 | HYDROXAMIC ACID DERIVATIVES | DARWIN DISCOVERY LTD (GB) | 2003-11-12 | — | — | EP | disclosed |
| EP-1282614-A1 | HYDROXAMIC ACID DERIVATIVES | Darwin Discovery Limited (GB) | 2003-02-12 | — | — | EP | disclosed |
| US-20020037900-A1 | Hydroxamic acid derivatives | DARWIN DISCOVERY LIMITED (GB) | 2002-03-28 | — | — | US | disclosed |
| WO-2001087870-A1 | HYDROXAMIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197448-A1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | PRSS1, PRSS3, HPN | CYP4F2 3019/4885CYP4A11 2083/4885NPSR1 2761/4885 |
| US-20020037900-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | CYP4F2 3956/4885CYP4A11 3358/4885NPSR1 3747/4885 |
| US-20030216404-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | CYP4F2 3956/4885CYP4A11 3358/4885NPSR1 3747/4885 |
| US-20040266764-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | CYP4F2 3956/4885CYP4A11 3358/4885NPSR1 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.